Long-term Ofatumumab Treatment Over 6 Years Did Not Increase the Risk of Serious Infections (P8-1.017)
To evaluate the risk of serious infections (SIs) with ofatumumab treatment over a period of 6 years (cutoff date: Sep 25, 2023) in people with relapsing multiple sclerosis (pwRMS).
Authors
- Valentine Jehl
- Scott S. Zamvil (ORCID: https://orcid.org/0000-0003-2720-9915)
- Min Wu (ORCID: https://orcid.org/0000-0001-5490-3916)
- Xavier Montalbán (ORCID: https://orcid.org/0000-0002-0098-9918)
- L. De Boer
- Sven Guenther Meuth (ORCID: https://orcid.org/0000-0003-2571-3501)
- Heinz Wiendl (ORCID: https://orcid.org/0000-0003-4310-3432)
- Gabriel Pardo (ORCID: https://orcid.org/0000-0002-2207-3708)
- Xixi Hu
- Roseanne Sullivan (ORCID: https://orcid.org/0000-0001-6025-465X)
- Jeffrey Cohen
- Alit Bhatt
Institutions
- Novartis (Switzerland) (CH)
- Cleveland Clinic (US)
- University of California, San Francisco (US)
- University of Münster (DE)
- Oklahoma Medical Research Foundation (US)
- Novartis (India) (IN)
- Novartis (United States) (US)
- Heinrich Heine University Düsseldorf (DE)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210613
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 0.00